Tetrahydro-azepinoquinolines as agonists of the 5-HT2C receptor
US10131660B2 · kind B2 · utility
0Cited by
1References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 26, 2015 |
| Grant date | Nov 20, 2018 |
| Priority date | — |
| Expiry date | Nov 2, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/24
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Certain tetrahydro-azepinoquinolines of structural formula I are agonists of the mammalian 5-HT2c receptor, and, in particular, are selective agonists of the mammalian 5-HT2c receptor. The compounds of the present invention are therefore useful for the treatment, control, or prevention of diseases, conditions, or disorders responsive to stimulation of the 5-HT2c receptor, such as obesity, obesity-related conditions, and certain CNS-related disorders, including schizophrenia and depression. They are also useful as aids for tobacco smoking cessation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.